Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...

Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.